Your browser doesn't support javascript.
loading
Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans.
Tuijnenburg, Paul; Lango Allen, Hana; Burns, Siobhan O; Greene, Daniel; Jansen, Machiel H; Staples, Emily; Stephens, Jonathan; Carss, Keren J; Biasci, Daniele; Baxendale, Helen; Thomas, Moira; Chandra, Anita; Kiani-Alikhan, Sorena; Longhurst, Hilary J; Seneviratne, Suranjith L; Oksenhendler, Eric; Simeoni, Ilenia; de Bree, Godelieve J; Tool, Anton T J; van Leeuwen, Ester M M; Ebberink, Eduard H T M; Meijer, Alexander B; Tuna, Salih; Whitehorn, Deborah; Brown, Matthew; Turro, Ernest; Thrasher, Adrian J; Smith, Kenneth G C; Thaventhiran, James E; Kuijpers, Taco W.
Afiliação
  • Tuijnenburg P; Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
  • Lango Allen H; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Burns SO; Department of Immunology, Royal Free London NHS Foundation Trust, University College London Institute of Immunity and Transplantation, London, United Kingdom.
  • Greene D; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Jansen MH; Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
  • Staples E; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Stephens J; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Carss KJ; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Biasci D; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Baxendale H; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Thomas M; Department of Immunology, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Chandra A; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Kiani-Alikhan S; Department of Immunology, Royal Surrey County Hospital, Guildford, United Kingdom.
  • Longhurst HJ; Department of Immunology, Barts Health NHS Trust, London, United Kingdom.
  • Seneviratne SL; Department of Immunology, Royal Free London NHS Foundation Trust, University College London Institute of Immunity and Transplantation, London, United Kingdom.
  • Oksenhendler E; Department of Clinical Immunology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris, France.
  • Simeoni I; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.
  • de Bree GJ; Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands.
  • Tool ATJ; Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands.
  • van Leeuwen EMM; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
  • Ebberink EHTM; Department of Plasma Proteins, Sanquin Research, Amsterdam, The Netherlands.
  • Meijer AB; Department of Plasma Proteins, Sanquin Research, Amsterdam, The Netherlands.
  • Tuna S; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Whitehorn D; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Brown M; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Turro E; Department of Haematology, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
  • Thrasher AJ; Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital NHS Trust London, London, United Kingdom.
  • Smith KGC; Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
  • Thaventhiran JE; Department of Medicine, University of Cambridge, Cambridge, United Kingdom. Electronic address: jedt2@cam.ac.uk.
  • Kuijpers TW; Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands; Department of Internal Medicine, Academic Medical Center,
J Allergy Clin Immunol ; 142(4): 1285-1296, 2018 10.
Article em En | MEDLINE | ID: mdl-29477724
ABSTRACT

BACKGROUND:

The genetic cause of primary immunodeficiency disease (PID) carries prognostic information.

OBJECTIVE:

We conducted a whole-genome sequencing study assessing a large proportion of the NIHR BioResource-Rare Diseases cohort.

METHODS:

In the predominantly European study population of principally sporadic unrelated PID cases (n = 846), a novel Bayesian method identified nuclear factor κB subunit 1 (NFKB1) as one of the genes most strongly associated with PID, and the association was explained by 16 novel heterozygous truncating, missense, and gene deletion variants. This accounted for 4% of common variable immunodeficiency (CVID) cases (n = 390) in the cohort. Amino acid substitutions predicted to be pathogenic were assessed by means of analysis of structural protein data. Immunophenotyping, immunoblotting, and ex vivo stimulation of lymphocytes determined the functional effects of these variants. Detailed clinical and pedigree information was collected for genotype-phenotype cosegregation analyses.

RESULTS:

Both sporadic and familial cases demonstrated evidence of the noninfective complications of CVID, including massive lymphadenopathy (24%), unexplained splenomegaly (48%), and autoimmune disease (48%), features prior studies correlated with worse clinical prognosis. Although partial penetrance of clinical symptoms was noted in certain pedigrees, all carriers have a deficiency in B-lymphocyte differentiation. Detailed assessment of B-lymphocyte numbers, phenotype, and function identifies the presence of an increased CD21low B-cell population. Combined with identification of the disease-causing variant, this distinguishes between healthy subjects, asymptomatic carriers, and clinically affected cases.

CONCLUSION:

We show that heterozygous loss-of-function variants in NFKB1 are the most common known monogenic cause of CVID, which results in a temporally progressive defect in the formation of immunoglobulin-producing B cells.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos B / Imunodeficiência de Variável Comum / Subunidade p50 de NF-kappa B Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos B / Imunodeficiência de Variável Comum / Subunidade p50 de NF-kappa B Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article